Showing 3401-3410 of 8741 results for "".
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3
- EADV News: Bimekizumab Achieves High Thresholds of Clinical Response in HShttps://practicaldermatology.com/news/eadv-news-bimekizumab-achieves-high-thresholds-of-clinical-response-in-hs/2462067/UCB’s Bimekizumab treatment results in clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) and the more stringent HiSCR75, HiSCR90 and HiSCR100 compared with placebo at Week 16, with improvements increasing for patients remaining in the study t
- Topical NFX-179 Inhibits MEK Activity, May Prevents SCChttps://practicaldermatology.com/news/topical-nfx-179-inhibits-mek-activity-may-prevents-scc/2462063/Topical NFX-179 may prevent the development of cutaneous squamous cell carcinoma in pre-clinical models, according to a
- Nemolizumab Performs Well in AD, PNhttps://practicaldermatology.com/news/nemolizumab-performs-well-in-ad-pn/2462061/Galderma’s nemolizumab performed well in three pivotal phase III trials in atopic dermatitis (AD) and prurigo nodularis (PN), according to late-breaking data presented at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin. Nemolizuma
- Incyte and Mandy Moore Partner to Empower People with AD in New Campaignhttps://practicaldermatology.com/news/incyte-and-mandy-moore-partner-to-empower-people-with-ad-in-new-campaign/2462060/Actress, singer and songwriter Mandy Moore is partnering with Incyte on
- EADV News: Continued Treatment with Opzelura (Ruxolitinib) Cream Shows Efficacy in Nonsegmental Vitiligohttps://practicaldermatology.com/news/eadv-news-continued-treatment-with-opzelura-ruxolitinib-cream-shows-efficacy-in-nonsegmental-vitiligo/2462059/Nonsegmental vitiligo patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura (Ruxolitinib) Cream for up to two years, according to new results of a pooled analysis of long-term ext
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.